Purdue, IU trustees voting on tuition freezes; Braun names new IU trustees
The Purdue University Board of Trustees will vote on a proposal Friday in West Lafayette to freeze tuition on in-state students, but raise rates for out-of-state and international students, in select majors.
At Purdue Northwest's Hammond and Westville campuses, a release said the proposal includes a 3% per-year tuition increase for non-resident and international students.
The increases at Northwest will be used to fund the operating budget, including faculty and staff salaries and benefits, scholarships, supplies, services, and repair and rehabilitation.
On the main campus for new and continuous international students, the undergraduate fee would increase by $500, a professional master's fee would increase $500 and the graduate fee would be $45 higher.
For out-of-state and international students enrolling for the first time in 2026 or later, the fees will increase by $1,000 for an undergraduate engineering fee; computer/data science and artificial intelligence undergraduate fee and for a business undergraduate fee.
Purdue said the fees would offset increased costs for specialized technology, equipment, facilities and/or have unique professional accreditation requirements changing.
In-state students on the main campus under the fiscal proposal would see no changes in rates for 2025-26 and 2026-27.
Meanwhile at Indiana University, trustees will hold a tuition forum at 12:15 p.m. June 12 prior to the start of the 3:30 regular meeting in Bloomington where the proposal will be considered.
In line with Gov. Mike Braun's recommendation, the Indiana Commission for Higher Education recommended tuition and mandatory fees at all seven of Indiana's public colleges and universities remain frozen for the 2025–2027 academic years.
The freeze amounts to a 5% budget decrease for the universities due to the $2.4 billion budget shortfall.
On Monday, Braun announced three new appointments to the IU Board of Trustees.
They include Sage Steele, a former ESPN anchor who left in 2023 after she was disciplined for remarks opposing the Walt Disney Company's COVID-19 vaccine mandate. She hosts a YouTube show and podcast and lives in Florida.
She graduated from IU-Bloomington in 1995.
James Bopp, of Terre Haute, is a well-known conservative attorney who opposed welcoming cities ordinances in Gary and East Chicago.
He also championed anti-abortion legislation.
Bopp received an undergraduate degree from IU in 1970. In 2021, Bopp represented 8 IU students who sued the school because of its COVID-19 vaccine mandate, but a federal court rejected their request for an injunction.
Brian Eagle, of Fishers, is an Indianapolis attorney, author and wealth strategy consultant. He's a 1986 IU graduate with an accounting degree.
Braun also reappointed Quinn Buckner, a former NBA player, and an executive with the Indianapolis Pacers. He became a trustee in 2016.
'I am confident that these appointees, who are all Indiana University alumni, will serve in the best interest of the university and will help guide IU back in the right direction as a premier flagship university in our state,' said Braun.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Bessent says US may 'roll the date forward' for some after 90-day tariff pause ends
(Reuters) -U.S. Treasury Secretary Scott Bessent on Wednesday said the Trump administration is prepared to "roll the date forward" with trading partners negotiating in good faith if the deadline marking the end of the 90-day pause on President Donald Trump's reciprocal tariffs is reached with no deal. "It is highly likely that those countries - or trading blocs as is the case with the EU - who are negotiating in good faith, we will roll the date forward to continue the good-faith negotiations," Bessent told the House Ways and Means Committee. "If someone is not negotiating, then we will not." Bessent's remarks, in response to a question from a Democratic lawmaker, marked the first time a Trump administration official has indicated some flexibility around the expiration date for the pause. That date - July 8 - is now just four weeks away, and so far the White House has struck only one preliminary deal with a major foreign trading partner affected by the pause, Britain. A deal struck on Tuesday in London with China to de-escalate that bilateral trade war is proceeding on a separate track and timeline. The White House did not immediately respond to a question about whether Trump shared Bessent's view. Trump announced the pause on April 9, a week after unveiling "Liberation Day" tariffs against nearly all U.S. trading partners that proved to be so unexpectedly large and sweeping that it sent global financial markets into near panic. The S&P 500 Index plunged more than 12% in four days for its heftiest run of losses since the onset of the COVID-19 pandemic in early 2020. Investors were so rattled they bailed out of safe-haven U.S. Treasury securities, sending bond yields rocketing higher. The dollar sank. Markets started their recovery on April 9 when Trump unexpectedly announced the pause. A further leg up in the recovery followed in early May when the Trump team reached a preliminary deal to dial back the triple-digit tariff rates it had imposed on goods from China. The events have given rise to what some on Wall Street have parodied as the "TACO" trade - an acronym for Trump Always Chickens Out. "The only time the market has reacted positively is when the administration is in retreat from key policy areas," Democratic Representative Don Beyer of Virginia told Bessent before pressing him on what should be expected at the end of the next deadline next month. "As I have said repeatedly there are 18 important trading partners. We are working toward deals with those," Bessent said before going on to signal a willingness to offer extensions to those negotiating in good faith. (Reporting By Dan Burns; Editing by Chris Reese and Daniel Wallis)
Miami Herald
37 minutes ago
- Miami Herald
AMC makes major theater change that will frustrate customers
AMC Theaters (AMC) had a rough start to 2025. The theater chain suffered a major loss as it struggled to attract moviegoers, despite major releases such as "Captain America: Brave New World," "Snow White," "Wolf Man," and "Dog Man." In its first-quarter earnings report for 2025, AMC revealed that its total revenues fell by about 9% year-over-year, while movie theater attendance in the U.S. dropped by 11%. Don't miss the move: Subscribe to TheStreet's free daily newsletter AMC also reported a net loss of $202.1 million during the quarter, which is higher than the $163.5 million net loss it suffered during the same quarter last year. Related: AMC announces generous offer to win back customers "Setting aside those first quarters directly impacted by Covid and its aftermath, the January to March industry box office in 2025 was the lowest it has been since 1996," said AMC CEO Adam Aron in the report. The dip in attendance comes after AMC's average movie ticket price in the U.S. reached $12.31 during the first quarter of this year, which is higher than the $12.19 average it reported for the same quarter in 2024. Movie ticket prices have been rising over the past few years amid inflation. According to recent data from The Numbers, the average movie ticket price in the U.S. was $11.31 in 2024, which is 3% higher than the $10.94 average in 2023. As prices increase, some consumers have been avoiding movie theaters like the flu. A recent survey from the Wall Street Journal found that 65% of consumers said they prefer to watch movies at home, while 35% said they prefer to watch films in theaters. Amid this trend, AMC has made a bold move to dodge further price increases; however, customers may not be thrilled about the decision. The theater chain has reportedly landed a deal with cinema advertising company National CineMedia to run more commercials before movie screenings begin, according to a recent report from The New York Times. AMC claims this deal will allow it to rely less on increasing movie ticket prices to boost its revenue. Related: Paramount makes drastic decision amid shift in customer behavior "For the past five years, AMC has sought out crucial revenue that is not reliant on the increase of base ticket prices," said AMC in a statement to the Times, adding "while AMC was initially reluctant to bring this to our theaters, our competitors have fully participated for more than five years without any direct impact to their attendance." The move from AMC comes after its top rivals, Regal and Cinemark, signed the same deal with National CineMedia in 2019. AMC was also offered the deal that same year; however, it "flatly rejected" it due to its concerns that "U.S. moviegoers would react quite negatively to the concept," according to a press release. The deal is expected to make pre-show advertisements last, on average, 20 to 30 minutes long. It is no surprise that AMC is continuing to dodge increasing its ticket prices as it has recently made several attempts to make moviegoing more affordable for consumers, who are battling inflation and higher costs of living. A few months ago, the theater chain added a new A-List Classic tier subscription to its flagship subscription service AMC Stubs A-List. The new tier offers a lower-price plan for guests who prefer to watch a maximum of one movie per week at AMC Classic locations. It also made several tweaks to AMC Stubs A-List to attract more frugal customers, such as expanding A-List weekly movie access from three titles a week to four, and lowering the age eligibility from 16 to 13 to attract more teens and families into theaters. During an earnings call in May, Aron said these changes are "designed to ease the pain of a healthy price increase." Related: Disney CEO offers unexpected response to tariff concerns The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
an hour ago
- Yahoo
History Shows the Danger of Trump's Health Policies
U.S. President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. attend an event in the East Room of the White House on May 22, 2025 in Washington, DC. Credit - Chip Somodevilla—Getty Images On May 11, 2023, President Joseph Biden ended the COVID-19 public health emergency, calling an finish to the pandemic. By the end of 2023, COVID-19 claimed the lives of over 20 million people around the world. But through international cooperation and evidence-based science, vaccines were developed and the world moved on. Indeed, perhaps the biggest success of the period was the quick production of a COVID-19 vaccine. The research behind the mRNA vaccine had been ongoing since the 1970s, but the emergency of the pandemic and international sharing of knowledge helped bring the vaccine to fruition. Today, the COVID-19 vaccine has been credited with saving 2.4 million lives around the world. But now, the U.S. is choosing competition over cooperation. With President Donald Trump's day one executive order to leave the World Health Organization (WHO)—blaming their COVID-19 response—and the shuttering of USAID, the country is taking steps towards further dividing health efforts across the globe. Here in the U.S., a sudden end to $11.4 billion of covid-related grants is stifling national pandemic preparedness efforts on the local and state levels. And most recently, Health and Human Services Secretary RFK Jr. purged experts from the CDC Advisory Committee, putting lives at risk. Historical lessons demonstrate the need for global health infrastructure that works together, shares knowledge, and remembers that pathogens do not stop at borders. White House's Pandemic Office, Busy With Bird Flu, May Shrink Under Trump One of the greatest global health achievements of all time—smallpox eradication—provides a perfect example of what can be done with independent scientific research and international cooperation. During the Cold War between the U.S. and USSR, decades of tension brought the world to the brink of nuclear war. Yet, incredibly, the nations managed to find common ground to support the efforts of smallpox eradication. Indeed, they understood the strategic benefits that came from letting public health practitioners and scientists work outside of political divides. The WHO was founded after World War II in 1948. Its formation marked a move from international health, that focused on nations, to global health, that would serve humanity first. The WHO's first eradication effort was the failed, U.S.-backed, Malaria Eradication Program from 1955 to 1969. The Smallpox Eradication Program, with intensive efforts beginning in 1967, provided a chance for redemption for the U.S. and WHO. For the United States, investing in disease eradication and poverty helped to mitigate growing backlash against the Vietnam War. In June of 1964, President Lyndon B. Johnson stated, 'I propose to dedicate this year to finding new techniques for making man's knowledge serve man's welfare.' He called for 1965—the same year he ordered ground troops to Vietnam to stop the spread of communism —to be a year of international cooperation that could bypass the politics of the Cold War. Previously, the USSR did not participate in the U.S. and WHO's first, failed global eradication plan for malaria. But upon rejoining the WHO in 1956, it was the Soviets who made the first call and investment into global eradication of smallpox in 1958. The WHO functioning as a mediator was crucial to allowing the USSR and the U.S. to work together. It allowed both nations to avoid giving credit to each other; rather success went to science itself. President Johnson called this 'a turning point' away from 'man against man' towards 'man against nature.' The limited role of politicians in the program proved to be key to its success. Scientists made decisions and worked together—no matter what country they came from—by focusing on disease and vaccination, not international tensions. The Soviet-initiated program was lead by Donald A. Henderson, a U.S. epidemiologist, who worked alongside the Russians until the last case of smallpox occurred in Somalia on October 26, 1977. During the 20th century, smallpox was responsible for an estimated 300 to 500 million deaths. Smallpox was officially declared eradicated by the WHO in October 1980, and is today still the only human disease to achieve this distinction. Less than a year after the declaration of smallpox eradication, the emergence of another pandemic, the HIV/AIDS crisis, reinforced the importance of science-first cooperation over politically-driven decision making. In June 1981, the first cases of a new unknown disease were reported in the CDC's Morbidity and Mortality Weekly Report. In short order, gay men were stigmatized and blamed in what would become one of the biggest public health disasters of all time. It took years of grassroots science-based activism to move beyond HIV/AIDS victim-blaming and find medical solutions. The Poster Child for AIDS Obscured as Much About the Crisis as He Revealed Too often, governments across the globe placed blame on the gay community for their 'sins' and did not provide needed support, leaving the sick to suffer and die. The pharmaceutical companies profited from the limited medications they had available and did not pursue sufficient development. The FDA process for new drugs was scheduled to take nine years, at a time when life expectancy after receiving an HIV/AIDS diagnosis was one year. These issues sparked activism, spawning the AIDS Coalition to Unleash Power (ACT UP) in 1987. ACT UP organizers took science into their own hands and began educating themselves. Members began reading scientific journals religiously, learning the chemistry and epidemiology of drug manufacturing and clinical trials. Members learned how to translate these dense scientific messages to educate the community members on what was—and what was not—being done to help. Because of this work, the FDA changed policies to allow for new treatments to be tested at accelerated rates in times of emergency. ACT UP was able to shift the cultural blame showing that the issue was a result of politics getting in the way of scientific advancements. By 1990, ACT UP influenced the largest federal HIV program to pass Congress, the Ryan White CARE Act. This program was a vital precursor to the 2003 PEPFAR (The U.S. President's Emergency Plan for AIDS Relief) global initiative. Both of these histories offer a powerful lesson: global health is national health, and national health is local health. With the recent funding cuts from the U.S. government, the future of global health is going in an unknown direction. And yet, the occurrence of pandemics is expected to increase in frequency due to climate change, mass migration, urbanization, and ecosystem destruction. It has been estimated that there is about a 25% chance we will have another COVID-sized pandemic within the next 10 years. No matter how secure the world makes borders, history shows that it can not protect us from disease if we do not have a strong, interconnected public health infrastructure. Luke Jorgensen is a Master of Public Health student at Purdue University where his epidemiology research examines human migration and infectious disease. Made by History takes readers beyond the headlines with articles written and edited by professional historians. Learn more about Made by History at TIME here. Opinions expressed do not necessarily reflect the views of TIME editors. Write to Made by History at madebyhistory@
